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Discussion
Dr John S. Ikonomidis (Charleston, SC). I would like to
congratulate Dr Bell for a very nice presentation and thank him
for sending me his slides and his presentation in advance. I have
a few questions. The first relates to the model. Conceptually
speaking in humans, 5 minutes of aortic occlusion really would
not be expected to produce the kind of spinal cord damage that
you saw in this model, so please explain briefly why you think
there are differences between mice and humans and put that in
the context of the potential clinical relevance of this study.
Dr Bell. I think 1 of the main differences within the spinal cords
is that the murine metabolic rate is much higher, so we are able to
see this injury under normothermic conditions at 5 minutes
compared with 45 minutes.
Dr Ikonomidis.While we are on the subject of hemodynamics
and heart rate, did you measure blood pressure during this study
and can you comment on blood pressure between the 2 groups?
Dr Bell.We previously looked at blood pressure with dexmede-
tomidine treatment before and after surgery, and did not see a dif-
ference in mice that were under the influence of isoflurane
anesthesia.
Dr Ikonomidis.What was the justification for the use of 25 mg
dexmedetomidine?
Dr Bell. It was done based on previous studies of neuroprotec-
tion with the middle cerebral artery occlusion model. It was seen
that the neuroprotective effects peaked at 25 mg/kg. This was
also a dose that caused no sedation and, we think, more correlated
with an anxiolytic dose.
Dr Ikonomidis. So if I were to give it to human patients, what
would be the intravenous dose?
Dr Bell. That is a great question. We haven’t been able to quan-
tify the exact amount for human patients. The intravenous dose is 1
mg/kg loaded over 10 minutes and then 0.5 mg/kg basal dosing.
Dr Ikonomidis. It strikes me that a lot of the data you presented
here are, to a large extent, associative, and I was wondering if you
have done specific mechanistic studies. For example, do you have
a cyclic AMP response-element binding (CREB) protein knockout
mouse in which you can abrogate spinal cord damage, or have you
done similar studies?
Dr Bell. CREB knockout mice are nonviable, but we have
developed our in vitro model, and we are able to grow these neu-
rons in a dish. We will be able to then use antibodies as well asery c January 2014
Bell et al Evolving Technology/Basic Sciencenucleotide inhibitors that we can further study to be able to nail
down that mechanism. These studies are going on currently.
Dr Ikonomidis. It is interesting that this model causes both
initial and delayed neurologic damage, so it mimics initial para-
plegia but also delayed paraplegia, and they both seem to be in-
hibited by dexmedetomidine. Can you comment on the potential
mechanisms? Are they similar or the same?
Dr Bell. In this experiment we chose 5 minutes because we
wanted to look at the initial ischemic insult and be able to associate
the observed injury with the ischemic insult. We, as well as others,
have looked at microglial activation and their contributions to de-
layed paralysis. Dexmedetomidine also has some anti-inflamma-
tory effects on microglial in vitro that could also contribute to
these findings. We did not treat them postoperatively because we
did not want to modify the inflammatory cascade in any way.
Dr Ikonomidis.Youmeasured protein kinase B (AKT) levels in
this study; an abundance of AKT. Did you look at any of its acti-
vating surrogates, such as phosphoinositide 3-kinase?
Dr Bell.No, we have not looked at that. It is something wewant
to do in vitro and to tie in more closely to the a-2 receptor, and I
think in vitro we could more easily do that.
Dr Ikonomidis. Thank you very much.
Dr Scott A. LeMaire (Houston, Tex). Dr Ikonomidis touched
on this, but my question relates to the potential use for this agonistThe Journal of Thoracic and Cafor not only treating acute injury we see early in the operating
room but also delayed injury. How long do the cellular effects of
this agonist persist? Do you have any data related to how long
the protective effects might last?
Dr Bell.Wewant to carry it out further in our murine model and
look at some of the chronic changes. We have observed that de-
layed paraplegia consistently occurs at 36 to 48 hours. We have
seen protection against delayed paraplegia as well when we
post-treated mice at reperfusion in a previous study. One of the po-
tential benefits of this drug is that you can keep a high-risk patient,
maybe an Extent 2 patient, in an intensive care unit on this drug
even when they are extubated on an anxiolytic dosing regimen.
Dr Pirooz Eghtesady (St Louis, Mo). I have a question related
to the 24-hour pretreatment. How did you come up with 24 hours
as opposed to 12 hours or a week, and howwould you translate that
to the clinical setting?
Dr Bell. We chose the pretreatment interval based on previous
models of ischemic preconditioning that showed a maximal effect
when the initial surgery of the sublethal ischemia was performed at
24 hours. We also believed that this interval would give us an
adequate time period for the expression of neuroprotective pro-
teins. In the clinical setting I think it would not be out of the ques-
tion to admit a patient the day before for an infusion of
dexmedetomidine at an anxiolytic dose.rdiovascular Surgery c Volume 147, Number 1 507
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